- Home
- TLSA vs CGTX Comparison
TLSA vs CGTX Comparison
Compare TLSA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | 25 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 132.4M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLSA | CGTX |
|---|---|---|
| Price | $1.47 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 439.7K | ★ 920.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.22 |
| 52 Week High | $2.60 | $3.83 |
Technical Indicators
Market Signals| Indicator | TLSA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 47.16 |
| Support Level | $1.39 | $1.46 |
| Resistance Level | $1.60 | $1.61 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 25.00 | 32.08 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.